The White House on Friday defended the Food and Drug Administration’s (FDA) approval of a second generic version of the abortion drug mifepristone, but said it shouldn’t be interpreted as an endorsement of the drug. The decision, made quietly before the government shutdown, means there are now three companies in the U.S. making mifepristone. It…

See Full Page